| 9.12 0.06 (0.66%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.66  |
1-year : | 14.33 |
| Resists | First : | 10.84 |
Second : | 12.27 |
| Pivot price | 10.19 |
|||
| Supports | First : | 8.52 |
Second : | 7.09 |
| MAs | MA(5) : | 9.12 |
MA(20) : | 10.24 |
| MA(100) : | 8.79 |
MA(250) : | 10.65 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 4.6 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 17.01 | Low : | 6.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PHAT ] has closed above bottom band by 22.3%. Bollinger Bands are 29.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.33 - 9.37 | 9.37 - 9.41 |
| Low: | 8.95 - 8.99 | 8.99 - 9.03 |
| Close: | 9.06 - 9.12 | 9.12 - 9.19 |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Fri, 19 Apr 2024
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Fri, 19 Apr 2024
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.7% - MarketBeat
Sun, 07 Apr 2024
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst - Seeking Alpha
Mon, 01 Apr 2024
Should Biotechnology Stock Phathom Pharmaceuticals Inc (PHAT) Be in Your Portfolio Monday? - InvestorsObserver
Thu, 28 Mar 2024
This Insider Has Just Sold Shares In Phathom Pharmaceuticals - Simply Wall St
Tue, 26 Mar 2024
What is the Market's View on Phathom Pharmaceuticals Inc (PHAT) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 4.323e+007 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 8,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6674e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 245.6 % |
| Return on Equity (ttm) | -36.2 % |
| Qtrly Rev. Growth | 682000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -138 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.6 |
| Dividend | 0 |
| Forward Dividend | 1.065e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|